PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY
Abstract
Authors
H. Price B. Schultes R. Prager J. Fernandes J.B. Møller M. Blüher